Tessera Therapeutics
PrivateLast Round
Grant
Mar 23, 2026
Total Funding Raised
$631.3M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Tessera Therapeutics is a biotechnology company that develops gene writing technology to facilitate permanent modifications to the human genome for therapeutic purposes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tessera Therapeutics Comparables
Compare Tessera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prime Medicine | 86% | |
| Integra Therapeutics | 83% | |
| Arbor Biotechnologies | 81% |
Tessera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 23, 2026 | ||||
| Grant | Oct 8, 2025 | ||||
| Strategic | Dec 18, 2024 | ||||
| Series C | Apr 19, 2022 | ||||
| Series B | Jan 12, 2021 | ||||
Seed | Jul 7, 2020 |
Key People
Founding team and executive leadership
Tessera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series C, Series B |
| Altitude Life Science Ventures | Series C, Series B |
| Cormorant Asset Management | Series C |
| Longevity Vision Fund | Series C |
| SALT | Series C |
| ARTIS Ventures | Series C |
| SoftBank Group | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 24, 2026
Partnering with Benchling for scientific software environment and ELN/registry platform.
- Mar 23, 2026
$41.3M raised in grant funding.
Recent news
Latest coverage and updates
- is_developingJul 24, 2026
Tessera Therapeutics is developing Gene Writing medicines on Jul 23rd '26.
- hiresJul 23, 2026
Tessera Therapeutics hired Joseph Romanelli as President and Chief Executive Officer on Jul 23rd '26.
- is_developingJul 23, 2026
Tessera Therapeutics, Inc. is developing in vivo gene editing therapy for sickle cell disease on Jul 23rd '26.
Tessera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Tessera Therapeutics's valuation, stock price, and market status.
Is Tessera Therapeutics a public or private company?
Tessera Therapeutics is a private company.
What is the current stock price of Tessera Therapeutics?
Tessera Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Tessera Therapeutics worth (valuation)?
Valuation information for Tessera Therapeutics is not publicly available.
Can I buy Tessera Therapeutics stock?
Tessera Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Tessera Therapeutics's last funding round?
Tessera Therapeutics's most recent funding round was Grant on March 23, 2026.
Who are the main investors in Tessera Therapeutics?
Key investors in Tessera Therapeutics include SoftBank Investment Advisers, Altitude Life Science Ventures, ARTIS Ventures, SoftBank Group, T. Rowe Price.
Will Tessera Therapeutics IPO soon?
No public IPO plans have been announced for Tessera Therapeutics.
How can I track Tessera Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tessera Therapeutics's secondary market activity and sign up for updates.